Ai Sirona (Luxembourg) Acquisition S.a.r.l (Zentiva)

Overview Key strengths Key risks Good ability to launch new products supported by both commercial and legal teams to obtain quick approvals across jurisdictions. Intense competitive environment. Established competitive positions in the generics market in Western and Eastern Europe. Small size relatively to largest generics players. Sound profitability with an EBITDA margin of about 22%. Limited presence in the most complex molecules segment. Sound portfolio diversification, with the top five products representing less than 4% of total sales. Exposure to large working capital requirements offset by factoring. According to data shared by the company, the European generics market to increase 3%-5% from 2023-2027, with a loss of exclusivity (LOE) estimated at €35 billion. Zentiva should benefit from this opportunity with

...Zentiva benefits from sound growth supported by its ability to launch new products and limited pricing pressure. According to data shared by the company, the European generics market to increase 3%-5% from 2023-2027, with a loss of exclusivity (LOE) estimated at 35 billion. Zentiva should benefit from this opportunity with new products, as reflected in its pipeline, which includes...

Full Report